COMMUNIQUÉS West-GlobeNewswire

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

07/11/2024 - 22:30

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents sufficient to fund [...]

Notice of General Meeting

07/11/2024 - 22:30

November 7, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of [...]

Teladoc Health Announces Employee Inducement Awards Under NYSE Rule 303A.08

07/11/2024 - 22:30

PURCHASE, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today announced that it issued inducement awards to two new employees. Effective November [...]

Tilray Medical annonce les résultats positifs d’une étude sur l’extrait de cannabis oral dans le traitement des vomissements induits par la chimiothérapie

07/11/2024 - 22:46

SYDNEY, Australie, 07 nov. 2024 (GLOBE NEWSWIRE) -- Tilray Medical, une division de Tilray Brands, Inc., ci-après « Tilray Brands » (NASDAQ : TLRY et TSX : TLRY) et leader mondial du cannabis thérapeutique, qui permet [...]

Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter

07/11/2024 - 23:00

World’s First Enhanced Small Particle (ESP™) Detection Sorter Enables Effective Content Isolation; Opens Door to Scientific Discoveries FREMONT, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq [...]

Nova Leap Health Corp. Posts Q3 2024 Results that include a Continuation of Consistent Operating Results and a Strong Balance Sheet.

07/11/2024 - 23:02

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Nov. 07, 2024 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]

Growth in revenue and operating profit

07/11/2024 - 17:12

Trading statement for Q1 2024/25 (1 July - 30 September 2024) Growth in revenue and operating profit Revenue was up 27% in the first quarter of 2024/25 to DKK 115.6 million from DKK 91.1 million in the year-earlier [...]

RAMSAY SANTE : Résultats du premier trimestre à fin septembre 2024

07/11/2024 - 17:35

COMMUNIQUÉ DE PRESSE Paris, le 7 novembre 2024 Résultats du premier trimestre à fin septembre 2024 Le chiffre d’affaires non audité du groupe a augmenté de 8,6 % pour atteindre 1,18 milliard d’euros, soutenu par des [...]

Ramsay Sante : Q1 results as of September 30, 2024

07/11/2024 - 17:35

PRESS RELEASE PRESS RELEASE Paris, 7 th November 2024 Q1 results as of September 30, 2024 Unaudited group revenue increased by 8.6% to €1.18bn supported by price increases and volume growth in France and Sweden [...]

Safe out of receivership

07/11/2024 - 17:50

Safe out of receivership Fleurieux-sur-l’Arbresle - France - November 6, 2024, 6.00 p.m. Safe SA and its subsidiaries announce that they have emerged from the court-ordered receivership proceedings by virtue of a ruling [...]

Ipsen - Octobre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

07/11/2024 - 18:00

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]

Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

07/11/2024 - 18:00

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

07/11/2024 - 18:27

Bagsværd, Denmark, 7 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]

Lowell Farms to Announce Third Quarter 2024 Financial and Operational Results

07/11/2024 - 19:06

California cannabis leader to hold earnings call on November 14, 2024 SALINAS, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (CSE:LOWL; OTCQX:LOWLF), a California-born cannabis company with advanced [...]

Third Harmonic Bio Announces Third Quarter 2024 Financial Results

07/11/2024 - 14:10

THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN FRANCISCO, Nov. 07, 2024 [...]

Trinity Biotech Regains Compliance with Nasdaq Listing Requirements

07/11/2024 - 14:19

DUBLIN, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable [...]

Merus annonce sa participation aux prochaines journées Investisseurs

07/11/2024 - 14:23

UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 07 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq : MRUS), une société du secteur de l’oncologie au stade clinique développant les anticorps multispécifiques de [...]

Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations

07/11/2024 - 14:30

Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) currently enrolling [...]

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

07/11/2024 - 14:30

Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc . (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for [...]